Wednesday, February 28, 2018

Marijuana Compound Removes Toxic Alzheimer’s Protein from the Brain

https://futurism.com/marijuana-compound-removes-toxic-alzheimers-protein-from-the-brain/
The results have been published in Aging and Mechanisms of Disease.

In Brief
Scientists have new evidence that suggests that THC inhibits the formation of amyloid plaques by blocking the enzyme in the brain that produces them. Neurodegenerative diseases such as Alzheimer's are caused by the poor formation of those proteins in the brain.
An active compound in marijuana called tetrahydrocannabinol (THC) has been found to promote the removal of toxic clumps of amyloid beta protein in the brain, which are thought to kickstart the progression of Alzheimer’s disease.

The finding supports the results of previous studies that found evidence of the protective effects of cannabinoids, including THC, on patients with neurodegenerative disease.
“Although other studies have offered evidence that cannabinoids might be neuroprotective against the symptoms of Alzheimer’s, we believe our study is the first to demonstrate that cannabinoids affect both inflammation and amyloid beta accumulation in nerve cells,” says one of the team, David Schubert from the Salk Institute for Biological Studies in California.
Schubert and his colleagues tested the effects of THC on human neurons grown in the lab that mimic the effects of Alzheimer’s disease.
If you’re not familiar with this special little compound, it’s not only responsible for the majority of marijuana’s psychological effects – including the high – thanks to its natural pain-relieving properties, it’s also been touted as an effective treatment for the symptoms of everything from HIV and chemotherapy to chronic pain, post-traumatic stress disorder, and stroke.
In fact, THC appears to be such an amazing medical agent, researchers are working on breeding genetically modified yeast that can produce it way more efficiently than it would be to make synthetic versions.
The compound works by passing from the lungs to the bloodstream, where it attaches to two types of receptors, cannabinoid receptor (CB) 1 and 2, which are found on cell surfaces all over the body.
In the brain, these receptors are most concentrated in neurons associated with pleasure, memory, thinking, coordination and time perception, and usually bind with a class of lipid molecules called endocannabinoids that are produced by the body during physical activity to promote cell-to-cell signaling in the brain.
But THC can also bind to them in much the same way, and when they do, they start messing with your brain’s ability to communicate with itself. The can be a good and a bad thing, because while you might forget something important or suddenly be incapable of swinging a baseball bat, you’ll probably feel amazing, and want to eat all the snacks:



Over the years, research has suggested that by binding to these receptors, THC could be having another effect on aging brains, because it appears to helps the body clear out the toxic accumulations – or ‘plaques’ – of amyloid beta.
No one’s entirely sure what causes Alzheimer’s disease, but it’s thought to result from a build-up of two types of lesions: amyloid plaques and neurofibrillary tangles.
Amyloid plaques sit between the neurons as dense clusters of beta-amyloid molecules – a sticky type of protein that easily clumps together – and neurofibrillary tangles are caused by defective tau proteins that clump up into a thick, insoluble mass in the neurons.
It’s not clear why these lesions begin to appear in the brain, but studies have linked inflammation in the brain tissue to the proliferation of plaques and neurofibrillary tangles. So if we can find something that eases brain inflammation while at the same time encourages the body to clear out these lesions, we could be on the way to finding the first effective treatment for Alzheimer’s ever.
Back in 2006, researchers at the Scripps Research Institute found that THC inhibits the formation of amyloid plaques by blocking the enzyme in the brain that produces them, and now Schubert and his team have demonstrated that it can also eliminate a dangerous inflammatory response from the nerve cells, ensuring their survival.
“Inflammation within the brain is a major component of the damage associated with Alzheimer’s disease, but it has always been assumed that this response was coming from immune-like cells in the brain, not the nerve cells themselves,” says one of the team, Antonio Currais.
“When we were able to identify the molecular basis of the inflammatory response to amyloid beta, it became clear that THC-like compounds that the nerve cells make themselves may be involved in protecting the cells from dying.”
It’s exciting stuff, but it’s so far only been demonstrated in neurons in the lab, so the next step will be for Schubert and his team to observe the link between THC and reduced inflammation and plaque build-up in a clinical trial. And they’ve reportedly already found a drug candidate called J147 that appears to have the same effects as THC, so this might be the way they can test the effects of THC without the government getting in the way.
The results have been published in Aging and Mechanisms of Disease.

Thursday, February 9, 2017

GW Pharmaceuticals Achieves Positive Results in Phase 2 Proof of Concept Study in Glioma

http://ir.gwpharm.com/releasedetail.cfm?ReleaseID=1010672

Feb 7, 2017
- GW intends to advance oncology research and development efforts -
LONDON, Feb. 07, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) ("GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced positive top-line results from an exploratory Phase 2 placebo-controlled clinical study of a proprietary combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) in 21 patients with recurrent glioblastoma multiforme, or GBM. GBM is a particularly aggressive brain tumor, with a poor prognosis. GW has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for THC:CBD in the treatment of glioma.
The study showed that patients with documented recurrent GBM treated with THC:CBD had an 83 percent one year survival rate compared with 53 percent for patients in the placebo cohort (p=0.042). Median survival for the THC:CBD group was greater than 550 days compared with 369 days in the placebo group. THC:CBD was generally well tolerated with treatment emergent adverse events leading to discontinuation in two patients in each group. The most common adverse events (three patients or more and greater than placebo) were vomiting (75%), dizziness (67%), nausea (58%), headache (33%), and constipation (33%). The results of some biomarker analyses are still awaited.
"The findings from this well-designed controlled study suggest that the addition of a combination of THC and CBD to patients on dose-intensive temozolomide produced relevant improvements in survival compared with placebo and this is a good signal of potential efficacy," said Professor Susan Short, PhD, Professor of Clinical Oncology and Neuro-Oncology at Leeds Institute of Cancer and Pathology at St James's University Hospital and principal investigator of the study. "Moreover, the cannabinoid medicine was generally well tolerated. These promising results are of particular interest as the pharmacology of the THC:CBD product appears to be distinct from existing oncology medications and may offer a unique and possibly synergistic option for future glioma treatment."
"We believe that the signals of efficacy demonstrated in this study further reinforce the potential role of cannabinoids in the field of oncology and provide GW with the prospect of a new and distinct cannabinoid product candidate in the treatment of glioma," stated Justin Gover, GW's Chief Executive Officer. "These data are a catalyst for the acceleration of GW's oncology research interests and over the coming months, we expect to consult with external experts and regulatory agencies on a pivotal clinical development program for THC:CBD in GBM and to expand our research interests in other forms of cancer."
The study, designed to evaluate a number of safety and efficacy endpoints, comprised an initial phase where the safety of THC:CBD in combination with dose-intense temozolomide (an oral alkylating agent that is a standard first-line treatment for GBM) was assessed in 2 cohorts of 3 patients each.  Following a satisfactory independent safety evaluation, the study then entered a randomized placebo-controlled phase where 12 patients were randomized to THC:CBD as add-on therapy compared with 9 patients randomized to placebo (plus standard of care). 
Beginning in 2007 and prior to initiating this study, GW conducted substantial pre-clinical oncologic research on several cannabinoids in various forms of cancer including brain, lung, breast, pancreatic, melanoma, ovarian, gastric, renal, prostate and bladder. These studies have resulted in approximately 15 publications and show the multi-modal effects of cannabinoids on a number of the key pathways associated with tumor growth and progression. Cannabinoids have been shown to promote autophagy (the process of regulated self-degradation by cells) via several distinct mechanisms, including acting on the AKT/mTOR pathway, an important intracellular signalling pathway that is overactive in many cancers.
In glioma, THC and CBD appear to act via distinct signalling pathways. The combination of THC and CBD showed good efficacy in various animal models of glioma, particularly when used in combination with temozolomide. Initial in vitro studies showed that the combined administration of THC and CBD led to a synergistic reduction in the viability of U87MG glioma cells when compared to the administration of each cannabinoid individually. The co-administration of temozolomide with THC and CBD had further synergistic effects, causing a significant reduction in cell viability. These pre-clinical studies justified the initiation of the Phase 2 clinical study.
GW's portfolio of intellectual property related to the use of cannabinoids in oncology includes a number of issued patents and pending applications in both the U.S. and Europe. This portfolio is designed to protect the use of various cannabinoids individually or in combination, in the treatment of a variety of oncology-specific disorders and product formulations.
About GBM
Gliomas are tumors that arise from glial cells mainly in the brain but can also be found within the spinal cord. Within the category of Glioma there are multiple different tumor types. GBM is the most common Glioma and is one of the most common primary brain tumors, accounting for 15.6% of all primary brain tumors (Ostrom et al. 2013). They are also the most aggressive with only 28.4% of patients surviving one year and only 3.4% surviving to year five (Brodbelt et al. 2015). Studies of patients with high-grade gliomas showed that headache was the most common initial presenting symptom. These headaches can be persistent lasting more than six months and are often associated with other symptoms, including seizures, visual disturbances, cognitive impairment and nausea and vomiting depending on the location and growth rate of the tumor.
About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex® (cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, Tuberous Sclerosis Complex and Infantile Spasms. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in 31 countries outside the United States. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy. For further information, please visit www.gwpharm.com.
Forward-looking statements
This news release contains forward-looking statements that reflect GW's current expectations regarding future events, including statements regarding financial performance, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions, the relevance of GW products commercially available and in development, the clinical benefits of Sativex® and Epidiolex® and the safety profile and commercial potential of Sativex and Epidiolex. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including (inter alia), the success of GW's research strategies, the applicability of the discoveries made therein, the successful and timely completion of uncertainties related to the regulatory process, and the acceptance of Sativex, Epidiolex and other products by consumer and medical professionals. A further list and description of risks and uncertainties associated with an investment in GW can be found in GW's filings with the U.S. Securities and Exchange Commission, including the most recent Form 20-F filed on 5 December 2016. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. GW undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Monday, December 26, 2016

Cannabinoid derivatives exert a potent anti-myeloma activity both in vitro and in vivo.

https://www.ncbi.nlm.nih.gov/pubmed/27778331

Friday, December 16, 2016

U.S.: Hemp Industry Association Says DEA Ruling Does Not Make CBD Illegal

http://crrh.org/news/blog/1582

By Derrick Stanley
Hemp News
The National Hemp Association has made an announcement that a recent ruling by the U.S. DEA (Drug Enforcement Administration) did not make cannabidoids (CBD) illegal.
The following statement was issued by the Hemp Industries Association:
Yesterday the Drug Enforcement Administration (DEA) issued a Final Rule on the coding of marijuana extracts. Unfortunately some misleading media stories and social media postings lead quite a few people to panic at reports that CBD was being banned under this new rule.
The Sky is NOT Falling. The Final Rule published by DEA did not change the legal status of CBD. This can only be done by a scheduling action which has NOT occurred.
HIA has carefully reviewed this with our legal advisors and discussed it with industry experts. While there are some differing opinions on the effect of the rule, there is general agreement that yesterday's ruling did not change the status of CBD. Here are some important facts to know:
Cannabidiol is not listed on the federal schedule of controlled substances
Sec. 7606 of the Farm Bill defines hemp as distinct from marijuana and does not treat it as a controlled substance when grown under a compliant state program.
Despite these facts, DEA has stated that CBD is a controlled substance previously.
- See more at: http://crrh.org/news/blog/1582#sthash.8DMXosgI.dpuf

By Derrick Stanley
Hemp News
The National Hemp Association has made an announcement that a recent ruling by the U.S. DEA (Drug Enforcement Administration) did not make cannabidoids (CBD) illegal.
The following statement was issued by the Hemp Industries Association:
Yesterday the Drug Enforcement Administration (DEA) issued a Final Rule on the coding of marijuana extracts. Unfortunately some misleading media stories and social media postings lead quite a few people to panic at reports that CBD was being banned under this new rule.
The Sky is NOT Falling. The Final Rule published by DEA did not change the legal status of CBD. This can only be done by a scheduling action which has NOT occurred.
HIA has carefully reviewed this with our legal advisors and discussed it with industry experts. While there are some differing opinions on the effect of the rule, there is general agreement that yesterday's ruling did not change the status of CBD. Here are some important facts to know:
Cannabidiol is not listed on the federal schedule of controlled substances
Sec. 7606 of the Farm Bill defines hemp as distinct from marijuana and does not treat it as a controlled substance when grown under a compliant state program.
Despite these facts, DEA has stated that CBD is a controlled substance previously.
HIA strongly disagrees with the DEA position and is ready to take action to defend should DEA take any action to block the production, processing or sale of hemp under Sec. 7606.
The Final Rule published on December 14th was not a scheduling action but rather an administrative action related to record keeping.
By Derrick Stanley
Hemp News
The National Hemp Association has made an announcement that a recent ruling by the U.S. DEA (Drug Enforcement Administration) did not make cannabidoids (CBD) illegal.
The following statement was issued by the Hemp Industries Association:
Yesterday the Drug Enforcement Administration (DEA) issued a Final Rule on the coding of marijuana extracts. Unfortunately some misleading media stories and social media postings lead quite a few people to panic at reports that CBD was being banned under this new rule.
The Sky is NOT Falling. The Final Rule published by DEA did not change the legal status of CBD. This can only be done by a scheduling action which has NOT occurred.
HIA has carefully reviewed this with our legal advisors and discussed it with industry experts. While there are some differing opinions on the effect of the rule, there is general agreement that yesterday's ruling did not change the status of CBD. Here are some important facts to know:
Cannabidiol is not listed on the federal schedule of controlled substances
Sec. 7606 of the Farm Bill defines hemp as distinct from marijuana and does not treat it as a controlled substance when grown under a compliant state program.
Despite these facts, DEA has stated that CBD is a controlled substance previously.
- See more at: http://crrh.org/news/blog/1582#sthash.8DMXosgI.dpuf
 
By Derrick Stanley
Hemp News
The National Hemp Association has made an announcement that a recent ruling by the U.S. DEA (Drug Enforcement Administration) did not make cannabidoids (CBD) illegal.
The following statement was issued by the Hemp Industries Association:
Yesterday the Drug Enforcement Administration (DEA) issued a Final Rule on the coding of marijuana extracts. Unfortunately some misleading media stories and social media postings lead quite a few people to panic at reports that CBD was being banned under this new rule.
The Sky is NOT Falling. The Final Rule published by DEA did not change the legal status of CBD. This can only be done by a scheduling action which has NOT occurred.
HIA has carefully reviewed this with our legal advisors and discussed it with industry experts. While there are some differing opinions on the effect of the rule, there is general agreement that yesterday's ruling did not change the status of CBD. Here are some important facts to know:
Cannabidiol is not listed on the federal schedule of controlled substances
Sec. 7606 of the Farm Bill defines hemp as distinct from marijuana and does not treat it as a controlled substance when grown under a compliant state program.
Despite these facts, DEA has stated that CBD is a controlled substance previously.
HIA strongly disagrees with the DEA position and is ready to take action to defend should DEA take any action to block the production, processing or sale of hemp under Sec. 7606.
The Final Rule published on December 14th was not a scheduling action but rather an administrative action related to record keeping.
- See more at: http://crrh.org/news/DEA-did-not-make-CBD-illegal-after-all-despite-reports-to-the-contrary#sthash.hLXbgO4d.dpuf
 
By Derrick Stanley
Hemp News
The National Hemp Association has made an announcement that a recent ruling by the U.S. DEA (Drug Enforcement Administration) did not make cannabidoids (CBD) illegal.
The following statement was issued by the Hemp Industries Association:
Yesterday the Drug Enforcement Administration (DEA) issued a Final Rule on the coding of marijuana extracts. Unfortunately some misleading media stories and social media postings lead quite a few people to panic at reports that CBD was being banned under this new rule.
The Sky is NOT Falling. The Final Rule published by DEA did not change the legal status of CBD. This can only be done by a scheduling action which has NOT occurred.
HIA has carefully reviewed this with our legal advisors and discussed it with industry experts. While there are some differing opinions on the effect of the rule, there is general agreement that yesterday's ruling did not change the status of CBD. Here are some important facts to know:
Cannabidiol is not listed on the federal schedule of controlled substances
Sec. 7606 of the Farm Bill defines hemp as distinct from marijuana and does not treat it as a controlled substance when grown under a compliant state program.
Despite these facts, DEA has stated that CBD is a controlled substance previously.
HIA strongly disagrees with the DEA position and is ready to take action to defend should DEA take any action to block the production, processing or sale of hemp under Sec. 7606.
The Final Rule published on December 14th was not a scheduling action but rather an administrative action related to record keeping.
- See more at: http://crrh.org/news/DEA-did-not-make-CBD-illegal-after-all-despite-reports-to-the-contrary#sthash.hLXbgO4d.dpuf
 
By Derrick Stanley
Hemp News
The National Hemp Association has made an announcement that a recent ruling by the U.S. DEA (Drug Enforcement Administration) did not make cannabidoids (CBD) illegal.
The following statement was issued by the Hemp Industries Association:
Yesterday the Drug Enforcement Administration (DEA) issued a Final Rule on the coding of marijuana extracts. Unfortunately some misleading media stories and social media postings lead quite a few people to panic at reports that CBD was being banned under this new rule.
The Sky is NOT Falling. The Final Rule published by DEA did not change the legal status of CBD. This can only be done by a scheduling action which has NOT occurred.
HIA has carefully reviewed this with our legal advisors and discussed it with industry experts. While there are some differing opinions on the effect of the rule, there is general agreement that yesterday's ruling did not change the status of CBD. Here are some important facts to know:
Cannabidiol is not listed on the federal schedule of controlled substances
Sec. 7606 of the Farm Bill defines hemp as distinct from marijuana and does not treat it as a controlled substance when grown under a compliant state program.
Despite these facts, DEA has stated that CBD is a controlled substance previously.
HIA strongly disagrees with the DEA position and is ready to take action to defend should DEA take any action to block the production, processing or sale of hemp under Sec. 7606.
The Final Rule published on December 14th was not a scheduling action but rather an administrative action related to record keeping.
- See more at: http://crrh.org/news/DEA-did-not-make-CBD-illegal-after-all-despite-reports-to-the-contrary#sthash.hLXbgO4d.dpuf
hemp field.jpg
By Derrick Stanley
Hemp News
The National Hemp Association has made an announcement that a recent ruling by the U.S. DEA (Drug Enforcement Administration) did not make cannabidoids (CBD) illegal.
The following statement was issued by the Hemp Industries Association:
Yesterday the Drug Enforcement Administration (DEA) issued a Final Rule on the coding of marijuana extracts. Unfortunately some misleading media stories and social media postings lead quite a few people to panic at reports that CBD was being banned under this new rule.
The Sky is NOT Falling. The Final Rule published by DEA did not change the legal status of CBD. This can only be done by a scheduling action which has NOT occurred.
HIA has carefully reviewed this with our legal advisors and discussed it with industry experts. While there are some differing opinions on the effect of the rule, there is general agreement that yesterday's ruling did not change the status of CBD. Here are some important facts to know:
Cannabidiol is not listed on the federal schedule of controlled substances
Sec. 7606 of the Farm Bill defines hemp as distinct from marijuana and does not treat it as a controlled substance when grown under a compliant state program.
Despite these facts, DEA has stated that CBD is a controlled substance previously.
HIA strongly disagrees with the DEA position and is ready to take action to defend should DEA take any action to block the production, processing or sale of hemp under Sec. 7606.
The Final Rule published on December 14th was not a scheduling action but rather an administrative action related to record keeping.
- See more at: http://crrh.org/news/DEA-did-not-make-CBD-illegal-after-all-despite-reports-to-the-contrary#sthash.hLXbgO4d.dpuf
hemp field.jpg
By Derrick Stanley
Hemp News
The National Hemp Association has made an announcement that a recent ruling by the U.S. DEA (Drug Enforcement Administration) did not make cannabidoids (CBD) illegal.
The following statement was issued by the Hemp Industries Association:
Yesterday the Drug Enforcement Administration (DEA) issued a Final Rule on the coding of marijuana extracts. Unfortunately some misleading media stories and social media postings lead quite a few people to panic at reports that CBD was being banned under this new rule.
The Sky is NOT Falling. The Final Rule published by DEA did not change the legal status of CBD. This can only be done by a scheduling action which has NOT occurred.
HIA has carefully reviewed this with our legal advisors and discussed it with industry experts. While there are some differing opinions on the effect of the rule, there is general agreement that yesterday's ruling did not change the status of CBD. Here are some important facts to know:
Cannabidiol is not listed on the federal schedule of controlled substances
Sec. 7606 of the Farm Bill defines hemp as distinct from marijuana and does not treat it as a controlled substance when grown under a compliant state program.
Despite these facts, DEA has stated that CBD is a controlled substance previously.
HIA strongly disagrees with the DEA position and is ready to take action to defend should DEA take any action to block the production, processing or sale of hemp under Sec. 7606.
The Final Rule published on December 14th was not a scheduling action but rather an administrative action related to record keeping.
- See more at: http://crrh.org/news/DEA-did-not-make-CBD-illegal-after-all-despite-reports-to-the-contrary#sthash.hLXbgO4d.dpuf
hemp field.jpg
By Derrick Stanley
Hemp News
The National Hemp Association has made an announcement that a recent ruling by the U.S. DEA (Drug Enforcement Administration) did not make cannabidoids (CBD) illegal.
The following statement was issued by the Hemp Industries Association:
Yesterday the Drug Enforcement Administration (DEA) issued a Final Rule on the coding of marijuana extracts. Unfortunately some misleading media stories and social media postings lead quite a few people to panic at reports that CBD was being banned under this new rule.
The Sky is NOT Falling. The Final Rule published by DEA did not change the legal status of CBD. This can only be done by a scheduling action which has NOT occurred.
HIA has carefully reviewed this with our legal advisors and discussed it with industry experts. While there are some differing opinions on the effect of the rule, there is general agreement that yesterday's ruling did not change the status of CBD. Here are some important facts to know:
Cannabidiol is not listed on the federal schedule of controlled substances
Sec. 7606 of the Farm Bill defines hemp as distinct from marijuana and does not treat it as a controlled substance when grown under a compliant state program.
Despite these facts, DEA has stated that CBD is a controlled substance previously.
HIA strongly disagrees with the DEA position and is ready to take action to defend should DEA take any action to block the production, processing or sale of hemp under Sec. 7606.
The Final Rule published on December 14th was not a scheduling action but rather an administrative action related to record keeping.
- See more at: http://crrh.org/news/DEA-did-not-make-CBD-illegal-after-all-despite-reports-to-the-contrary#sthash.hLXbgO4d.dpuf

Friday, November 25, 2016

Cannabinoids Improve Efficiency Of Mitochondria And Remove Damaged Brain Cells

http://www.collective-evolution.com/2013/05/30/new-study-shows-cannabinoids-improve-efficiency-of-mitochondria-and-remove-damaged-brain-cells/

mary j
  We're creating a positive news network. We need your help.
mjA recent study conducted by Andras Biokei-Gorzo at the Institute of Molecular Psychiatry at the University of Bonn in Germany is suggesting that marijuana(or the activation of the brain’s cannabinoid system) triggers the release of antioxidants, which act as a cleansing mechanism. This process is known to remove damaged cells and improve the efficiency of mitochondria. Mitochondria is the energy source that powers cells.  The study was published in Philosophical Transactions Of The Royal Society, B. You can read the entire study here.
These discoveries shed new insight on how natural marijuana cannabinoids hold the capacity to literally kill the brain inflammation responsible for causing cognitive decline, neural failure, and brain degeneration. By supplying these receptor sites with cannabinoids, patients may be able to overcome brain conditions like Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and more, not to mention premature brain aging. The human brain contains an extensive network of special receptor sites that modulate nervous system function only when activated by the appropriate cannabinoid compounds, which are found in the marijuana plant.
Cannabinoids refer to any of a group of related compounds that include cannabinol and the active constituents of cannabis. They activate canbinoid receptors in the body. The body itself produces  compounds called endocannabinoids and they play a role in many processes within the body that help to create a healthy environment. Cannabinoids also play a role in immune system generation and re-generation. The body regenerates best when it’s saturated with Phyto-Cannabinoids. Cannabinoids can also be found in Cannabis. Cannabinoids may very well be the best cancer fighting substance out there!
Cannabinoid system activity is neuroprotective, and increasing it could be a promising strategy for slowing down the progression of brain aging and for alleviating the systems of neurodegenerative disorders -Andras Biokei
Gery Wenk, a professor of neuroscience, immunology and medical genetics at Ohio State University conducted some of the research that came out of the study from Germany. He stated that this is a positive step, and that it is encouraging to see the potential development of cannabinoid solutions without going overboard. Here is what he said.
I’ve been trying to find a drug that will reduce brain inflammation and restore cognitive function in rats for over 25 years; cannabinoids are the first and only class of drugs that have ever been effective. I think that the perception about this drug is changing and in the future people will be less fearful. – Gerry Wenk, Professor of neuroscience, immunology and medical genetics at Ohio State University
Biokei-Gorzo and his collegues said that the greatest hurdle for moving forward with their research are the social and political challenges. This isn’t something new, our world seems to be dominated by belief systems instead of obvious fact. It’s discouraging to see beliefs  and persuasion overrule truth. At the same time it’s very encouraging to see truth slowly creep its way into the norm. That’s always how it has been done throughout human history. It’s quite evident that the powers that be do not want to legalize marijuana, and we know that they do not have our best interest at hand. If it was legalized, I’m sure it would be distributed and tweaked by big pharmaceutical companies.
On the other hand there have been a number of studies that show how marijuana can actually reduce brain power and impair working memory. The amount of studies that show the potential benefits of marijuana is outstanding, and the potential harmful effects are in the few, if any at all. As far as medicinal use goes, I think that is a no brainer. I definitely believe nature intended marijuana to be used for its health and healing properties.
Sources:
http://cannabisinternational.org/
http://edrv.endojournals.org/content/27/1/73.fullhttp://cannabisclinicians.org/wp-content/uploads/2011/12/OS-2011-Terpenes+Minor-CBs.pdf

Friday, September 23, 2016

U.S. Attorney General Admits Marijuana Is Not a Gateway Drug

https://www.merryjane.com/news/us-attorney-general-admits-marijuana-not-gateway-drug

Top federal official crushes this popular anti-legalization argument.

One of the most popular arguments against the legalization of marijuana is that pot is a “gateway” drug with the potential to turn the great American populous into a nation of dope fiends. But today the country’s leading law enforcement official denounced this common misconception by admitting that the consumption of marijuana does not lead to the use of harder drugs.
As part of what President Obama has declared National Prescription Opioid and Heroin Epidemic Awareness Week, U.S Attorney General Loretta Lynch appeared at town hall meeting this morning in Richmond, Kentucky to discuss the dangers of opioid abuse with a group of teens.
In her opening statement, Lynch was adamant that the leading culprit behind Kentucky’s heroin epidemic was the use of prescription drugs.
“When you look at someone that, for example, has a heroin problem, it very often started with a prescription drug problem. Something totally legal. Something in every medicine cabinet. Something you can have prescribed to you in good faith by a doctor,” Lynch said before taking questions from the audience.
It did not take long before the discussion turned to the issue of marijuana.
Tyler Crafton, a student at Madison Central High School, took the opportunity to ask Lynch whether she thought the recreational use of marijuana among high school kids would lead to opioid abuse.
Shockingly, Lynch, the top dog at the U.S. Department of Justice, did provide the young man with a response straight out of the federal government’s propaganda handbook.
“There a lot of discussion about marijuana these days. Some states are making it legal, people are looking into medical uses for it, and I understand that it still is as common as almost anything,” Lynch replied. “When we talk about heroin addiction, we unusually, as we have mentioned, are talking about individuals that started out with a prescription drug problem, and then because they need more and more, they turn to heroin. It isn’t so much that marijuana is the step right before using prescription drugs or opioids.”
For a moment, it sounded as though the Attorney General was preparing to backtrack on her statement to some degree, adding that, “if you tend to experiment with a lot of things if life you may be more inclined to experiment with drugs.”
But then Lynch followed up with what should be considered one of the most important statements a federal official has made in 2016.
“It’s not as though we are seeing that marijuana is a specific gateway,” she said.
The attorney general’s admission that marijuana is not a gateway drug is fairly consistent with the National Institute on Drug Abuse, which finds “the majority of people who use marijuana do not go on to use other, “harder” substances. Yet many of marijuana’s opposing forces are going up against ballot measure in several states this election season by trying to convince the general public that legal weed will cause the opioid epidemic to spin further out of control.
Interestingly, an investigational report published earlier this week by the Associated Press and the Center for Public Integrity found that lobbyists for the drug makers responsible for the same prescription drugs that Attorney General Lynch says is responsible for the opioid epidemic have spent $880 million legally bribing state representatives and senators to vote against legislation concerning the restricting of opioid use. It stands to reason that these lobbyists are also responsible for getting federal lawmakers to turn a blind eye to marijuana.
Attorney General Lynch will be speaking at more than 250 events this week in support of Prescription Opioid and Heroin Epidemic Awareness Week. It will be interesting to see if she offers additional comments about the safety of marijuana.

Tuesday, September 20, 2016

Where to find good quality RSO or Hemp Extracts?

I get this question quite a bit, if you aren't able to make the oil yourself, then here is a list of legit providers

California
California Tears CBD and RSO
Synergy Wellness

Oregon
Genesis Pharms

Worldwide
Hemp Oil Shop


Monday, September 5, 2016

Boy on His Deathbed is Cured with Cannabis

1455762186682
In a last ditch effort to save his life, 17-year-old Alexander “AJ” Kephart’s dedicated parents, Sheila and Chris, decided to try out cannabis oil on their dying son with miraculous results. Here’s one American family’s painful, inspirational, devastating and heroic medical cannabis cures-cancer story.
AJ’s super supportive father, Chris, admits his son’s story is complicated–even doctors have a hard time understanding everything he is now “missing” and how he’s been put back together (with titanium, prosthetics and even a “cage” around his back after having three vertebrae removed).
It all started in August 2012 when AJ noticed a persistent pain in his knee. In January 2013, he was diagnosed as having bone cancer. Later it was found that he also had stage four lung carcinoma as well.
That’s when AJ started chemotherapy. In May of the same year, his entire knee was removed along with some bone in his thigh and calf. At this point, doctors also found six tumors on all four of his lung chambers. To keep his lungs from collapsing, AJ was kept in the hospital for months hooked up to a breathing apparatus.
AJ was healing up when the cancer returned in 2014. He had his first three vertebrae removed, his top two ribs and sections of his back removed. The surgery itself even had to be stopped halfway as AJ was losing the use of his nerves. He ended up having to wear a cage around his body until the surgery could be completed a week or so later.
Just a few months after the spine surgery, AJ’s oncologist, Dr. Susan Storch, informed Sheila and Chris that his left lung lobe was covered with 20 plus cancerous tumors. They started chemo. Again.
Aj
That’s when they got the news: It’s time to “get your son’s things in order,” said the doctors. They gave AJ only a month more to live.
In complete desperation, Sheila and Chris asked their doctor about medical cannabis and its cancer-fighting effects. Dr. Storch agreed cannabis oil would be a good “alternative” medicine to pursue along with another series of chemotherapy sessions. She recommended cannabis pioneer Dr. Bonni Goldstein.
In her Lawndale, California office, Dr. Goldstein explained how cannabinoids–especially CBD–work by telling cancer cells to commit suicide plus it stops the formation of new capillaries, which cancer cells need to grow and spread. But even Dr. Goldstein had to admit AJ’s case was going to be experimental as she has never before treated a child with this particular cancer.
On the way home to Simi Valley, the Kepharts made a stop in Beverly Hills to Tracy Ryan’s then new cannabis clinical built specifically for children, CannaKids. “When we met AJ, he was super frail and was wearing a neck brace. He was taking handfuls of pain medications daily. His Mother Sheila was terrified and she looked like her soul had been ripped out,” remembers Ryan, whose daughter Sophie was healed of a brain tumor via cannabis oil.
In fact, AJ was in excruciating pain. His father Chris says AJ was taking two of the following each day for pain: OxyContin, Norco, Tylenol and Motrin. Without the pain killers, AJ would scream and cry in horrendous pain whenever he was awake.
After five days on CBD and THC oils by CannaKids, Chris says AJ’s pain has decreased so much that he was down to taking only one OxyContin daily. “Wow,” he exclaimed when remembering this stress-relieving moment for the whole family.
Because AJ had nothing to lose, his loving parents decided to speed up the dosage process. Dr. Goldstein had recommended a three-month process to increase the dosage, but Chris decided to fly at warp speed.
In two weeks, AJ was up to the highest dosage, but he was also tired all the time and felt loopy. “No, son,” father Chris said to AJ, “you are just stoned out of your mind.” Chris admits that this was a sad, but comical moment for father and son.
Two months later, the Kepharts visited their oncologist who was shocked that AJ looked much better and stronger. She also discovered his white blood cell counts showed lots of improvement. Four months later, a scan showed the multiple tumors on AJ’s lungs were completely gone.
Chris says Dr. Storch told them something like: “I can’t explain it. There’s no reason for it. But your scan came back totally clear. There’s no cancer. There’s no tumors in his lungs. It’s all gone.”
Since then, every scan has shown there’s no longer any cancer. “I believe cannabis is keeping him alive,” says Chris.
Very unfortunately, high dosage medical grade cannabis oil is expensive and costs the Kepharts almost $2,000 a month to keep AJ cancer and pain free. The stress this financial burden has put on the family has even affected AJ’s mental health.
“He was freaking out about everything,” says Chris, who made sure to provide AJ with a psychotherapist and as relaxing an environment as he can provide given the extreme circumstances.
Today, AJ is still cancer free. He has completely stopped chemotherapy after having more complications. He and his family are seeking less expensive ways to get high-grade cannabis oils, but they have yet to find a more affordable answer before this health crisis literally puts the family in bankruptcy.
AJ’s very brave cancer survival story truly is a medical miracle and another reason cannabis needs to be legalized and affordable for everyone who needs it.
www.gofundme.com/ajkephart

http://ireadculture.com/boy-on-his-deathbed-is-cured-with-cannabis/

normally we do not post testimonials, but this one was especially touching

Tuesday, August 23, 2016

New July 2016 Granny's Storm Crow List

To: stormcrow 

I've put the List on the cloud! Click the link to download the new
2016 Granny Storm Crow's List!

https://1drv.ms/b/s!AkiTiWAuHrKLbx7-n63PHKx_T9I

Just opening the link will show you the List, but you will need to
download it to access the very useful Navigation Index. Click the
"Bookmark" icon if it doesn't automatically show up. No more scrolling
"forever" to get to that study you want!  It may take a minute or so
to download- it's over 3,300 pages!

The first section of the List is over 475 pages of links to news
articles, so you won't need a PhD to use the List. Reading a news
article about something first, really makes understanding the actual
medical study much easier!

The second section is devoted to the more recent medical studies and
articles from 2010 to the beginning of August 2016. For people
seriously looking into cannabis and the cannabinoids, this will likely
be the most useful section for a lot of you.

Further down are the older studies that go into detail about some of
the basic questions (how long to hold a hit, storage of cannabis,
effects on hormone levels, etc). The older studies also tend to be
easier to understand, so they are a good place to begin your
education.

At the very bottom is a small mini-dictionary of words you will run
across in the studies. You might even want to print up a copy of it just
as a handy reference until you get used to all of the "Sci-speak"!

And take your Omega 3! It is needed to properly make the CB receptors
that the cannabinoids (like THC and CBD) activate to get you "high",
and also, more importantly, heal you. You want lots of working CB
receptors, and not just for the better "high" that daily use of Omega
3 can bring after a month or two!

And one last thank you to "Old Hippie" (of the "Beyond Chronic" blog)
for his invaluable technical help in getting this List out to all of
you! "Nugs and Hugs" to you, my friend!

I hope you enjoy my List,

Granny

Monday, August 1, 2016

Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis.

http://www.ncbi.nlm.nih.gov/pubmed/26517407
Eur J Pain. 2016 Jul;20(6):936-48. doi: 10.1002/ejp.818. Epub 2015 Oct 30.

Abstract

BACKGROUND:

Current arthritis treatments often have side-effects attributable to active compounds as well as route of administration. Cannabidiol (CBD) attenuates inflammation and pain without side-effects, but CBD is hydrophobic and has poor oral bioavailability. Topical drug application avoids gastrointestinal administration, first pass metabolism, providing more constant plasma levels.

METHODS:

This study examined efficacy of transdermal CBD for reduction in inflammation and pain, assessing any adverse effects in a rat complete Freund's adjuvant-induced monoarthritic knee joint model. CBD gels (0.6, 3.1, 6.2 or 62.3 mg/day) were applied for 4 consecutive days after arthritis induction. Joint circumference and immune cell invasion in histological sections were measured to indicate level of inflammation. Paw withdrawal latency (PWL) in response to noxious heat stimulation determined nociceptive sensitization, and exploratory behaviour ascertained animal's activity level.

RESULTS:

Measurement of plasma CBD concentration provided by transdermal absorption revealed linearity with 0.6-6.2 mg/day doses. Transdermal CBD gel significantly reduced joint swelling, limb posture scores as a rating of spontaneous pain, immune cell infiltration and thickening of the synovial membrane in a dose-dependent manner. PWL recovered to near baseline level. Immunohistochemical analysis of spinal cord (CGRP, OX42) and dorsal root ganglia (TNFα) revealed dose-dependent reductions of pro-inflammatory biomarkers. Results showed 6.2 and 62 mg/day were effective doses. Exploratory behaviour was not altered by CBD indicating limited effect on higher brain function.

CONCLUSIONS:

These data indicate that topical CBD application has therapeutic potential for relief of arthritis pain-related behaviours and inflammation without evident side-effects.
© 2015 European Pain Federation - EFIC®
PMID:
26517407
PMCID:
PMC4851925
DOI:
10.1002/ejp.818
[PubMed - in process]
Free PMC Article

Monday, July 25, 2016

Anticancer mechanisms of cannabinoids.

http://www.ncbi.nlm.nih.gov/pubmed/27022311

Curr Oncol. 2016 Mar;23(2):S23-32. doi: 10.3747/co.23.3080. Epub 2016 Mar 16.

Abstract

In addition to the well-known palliative effects of cannabinoids on some cancer-associated symptoms, a large body of evidence shows that these molecules can decrease tumour growth in animal models of cancer. They do so by modulating key cell signalling pathways involved in the control of cancer cell proliferation and survival. In addition, cannabinoids inhibit angiogenesis and decrease metastasis in various tumour types in laboratory animals. In this review, we discuss the current understanding of cannabinoids as antitumour agents, focusing on recent discoveries about their molecular mechanisms of action, including resistance mechanisms and opportunities for their use in combination therapy. Those observations have already contributed to the foundation for the development of the first clinical studies that will analyze the safety and potential clinical benefit of cannabinoids as anticancer agents.

KEYWORDS:

Cannabinoids; angiogenesis; apoptosis; autophagy; cell proliferation; cell signalling; combination therapy

Wednesday, June 29, 2016

Cannabinoids remove plaque-forming Alzheimer’s proteins from brain cells

http://www.salk.edu/news-release/cannabinoids-remove-plaque-forming-alzheimers-proteins-from-brain-cells/


Preliminary lab studies at the Salk Institute find THC reduces beta amyloid proteins in human neurons
LA JOLLA–Salk Institute scientists have found preliminary evidence that tetrahydrocannabinol (THC) and other compounds found in marijuana can promote the cellular removal of amyloid beta, a toxic protein associated with Alzheimer’s disease.
While these exploratory studies were conducted in neurons grown in the laboratory, they may offer insight into the role of inflammation in Alzheimer’s disease and could provide clues to developing novel therapeutics for the disorder.
“Although other studies have offered evidence that cannabinoids might be neuroprotective against the symptoms of Alzheimer’s, we believe our study is the first to demonstrate that cannabinoids affect both inflammation and amyloid beta accumulation in nerve cells,” says Salk Professor David Schubert, the senior author of the paper.
Alzheimer’s disease is a progressive brain disorder that leads to memory loss and can seriously impair a person’s ability to carry out daily tasks. It affects more than five million Americans according to the National Institutes of Health, and is a leading cause of death. It is also the most common cause of dementia and its incidence is expected to triple during the next 50 years.
It has long been known that amyloid beta accumulates within the nerve cells of the aging brain well before the appearance of Alzheimer’s disease symptoms and plaques. Amyloid beta is a major component of the plaque deposits that are a hallmark of the disease. But the precise role of amyloid beta and the plaques it forms in the disease process remains unclear.
David-Schubert
David Schubert, Professor of Salk’s Cellular Neurobiology Laboratory Click here for a high resolution image
Credit: Salk Institute
In a manuscript published in June 2016’s Aging and Mechanisms of Disease, the Salk team studied nerve cells altered to produce high levels of amyloid beta to mimic aspects of Alzheimer’s disease.
The researchers found that high levels of amyloid beta were associated with cellular inflammation and higher rates of neuron death. They demonstrated that exposing the cells to THC reduced amyloid beta protein levels and eliminated the inflammatory response from the nerve cells caused by the protein, thereby allowing the nerve cells to survive.
“Inflammation within the brain is a major component of the damage associated with Alzheimer’s disease, but it has always been assumed that this response was coming from immune-like cells in the brain, not the nerve cells themselves,” says Antonio Currais, a postdoctoral researcher in Schubert’s laboratory and first author of the paper. “When we were able to identify the molecular basis of the inflammatory response to amyloid beta, it became clear that THC-like compounds that the nerve cells make themselves may be involved in protecting the cells from dying.”
Brain cells have switches known as receptors that can be activated by endocannabinoids, a class of lipid molecules made by the body that are used for intercellular signaling in the brain. The psychoactive effects of marijuana are caused by THC, a molecule similar in activity to endocannabinoids that can activate the same receptors. Physical activity results in the production of endocannabinoids and some studies have shown that exercise may slow the progression of Alzheimer’s disease.
Schubert emphasized that his team’s findings were conducted in exploratory laboratory models, and that the use of THC-like compounds as a therapy would need to be tested in clinical trials.
In separate but related research, his lab found an Alzheimer’s drug candidate called J147 that also removes amyloid beta from nerve cells and reduces the inflammatory response in both nerve cells and the brain. It was the study of J147 that led the scientists to discover that endocannabinoids are involved in the removal of amyloid beta and the reduction of inflammation.
Other authors on the paper include Oswald Quehenberger and Aaron Armando at the University of California, San Diego; and Pamela Maher and Daniel Daughtery at the Salk Institute.
The study was supported by the National Institutes of Health, The Burns Foundation and The Bundy Foundation.
PUBLICATION INFORMATION

JOURNAL
Aging and Mechanisms of Disease
AUTHORS
Antonio Currais, Oswald Quehenberger, Aaron M Armando, Daniel Daugherty, Pam Maher & David Schubert

Tuesday, January 19, 2016

Marijuana helps Alzheimer’s patients, study finds

http://blog.sfgate.com/smellthetruth/2016/01/14/marijuana-helps-alzheimers-patients-study-finds/

Alzheimer's Disease patients benefited from marijuana, Israeli researchers report. Above, Julianne Moore in 2015's 'Still Alice'.
Alzheimer’s Disease patients benefited from marijuana, Israeli researchers report. Above, Julianne Moore in 2015’s ‘Still Alice’.
Adding marijuana to the treatment of Alzheimer’s Disease “is safe and a promising treatment option”, Israeli researchers conclude, in the latest study on the burgeoning practice.
Alzheimer’s Disease is a devastating and fatal degenerative neurological disease affecting more than five million Americans today. One in three seniors will die with Alzheimer’s or another dementia, and Alzheimer’s is the sixth leading cause of death in the nation, costing America about $203 billion in 2013.
Past studies indicate the active ingredients in cannabis can provide palliative relief to Alzheimer’s patients with dementia — calming them down and allowing them to sleep. Cell studies also indicate cannabis’ active ingredients could prevent the onset and progression of Alzheimer’s, by interrupting the cycle of beta-amyloid plaque creation thought to cause Alzheimer’s Disease.
Researchers at the Abarbanel Mental Health Center and the Sackler Faculty of Medicine at Tel-Aviv University, in Israel, along with the Department of Psychology, at Bar-Ilan University conducted one of the first clinical studies of cannabis on human Alzheimer’s patients.
The main active ingredient in cannabis “tetrahydrocannabinol (THC) is a potential treatment for Alzheimer’s disease (AD)” researchers wrote. They wanted to measure the safety and efficacy of giving a medical cannabis oil containing THC as an add-on to existing Alzheimer’s drugs. Their goal: relieving the terrifying behavioral and psychological symptoms of dementia.
Eleven patients were recruited into an open-label, month-long trial. Ten patients finished the trial, and researchers reported “significant reduction” in mental illness severity, especially with regard to delusions, agitation/aggression, irritability, apathy, sleep, and caregiver distress.
“Adding [medical cannabis oil] to [Alzheimer’s Disease] patients’ pharmacotherapy is safe and a promising treatment option,” researchers concluded.
Read: “Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study
Smell the Truth editor David Downs is the author of The Medical Marijuana Guidebook, out in paperback this February (Whitman Publishing).

Sunday, October 11, 2015

Here's What Marijuana Does to Pain


http://www.attn.com/stories/3515/what-marijuana-does-to-pain

Here's What Marijuana Does to Pain

For people suffering from chronic pain, treatment options are generally limited. You can take prescription painkillers such as Vicodin or Oxycotin, but while they might alleviate your discomfort, they are also addictive and dangerous. And as the U.S. continues to struggle with rising rates of opiate addiction, the search is on for a safer alternative. Cannabis appears to be a good candidate.

RELATED: What Does Marijuana Do To Your Sleep Patterns?

 


A new study published in the Journal of Pain found that chronic pain patients who used marijuana for one year had reduced discomfort, improved quality of life, and experienced no increased risk of serious side effects. McGill University researchers analyzed reports from 216 cannabis users and 215 non-users, finding that pot is effective at treating pain.
"[W]e noted significant improvements in pain intensity and the physical dimension of quality of life over one year among the cannabis users compared to controls," the researchers wrote. "There was also significant improvement among cannabis users in measures of the sensory component of pain, symptom distress, and total mood disturbance compared to controls."

RELATED: Marijuana Might Actually be an Anti-Gateway Drug

This isn't the first study to look at the effects of marijuana on pain. In 2009, the National Association of Boards of Pharmacy announced that cannabis could help with "multiple pain syndromes," including neuropathic (burning), mechanical (aching), and inflammatory (acute, sharp) pain. Not only is the substance an effective analgesic, but it also carries "minimal physical dependence" with limited drug interactions, the organization wrote.
What's more, a review of cannabis trials published in the British Journal of Clinical Pharmacology concluded that "it is reasonable to consider cannabinoids as a treatment option for the management of chronic neuropathic pain with evidence of efficacy in other types of chronic pain such as fibromyalgia and rheumatoid arthritis as well."
And a 2013 study published in the Clinical Journal of Pain found that "cannabinergic pain medicines have been shown to be modestly effective and safe treatments in patients with a variety of chronic pain conditions," leading researchers to conclude that incorporating medical cannabis into pain medicine education "seems warranted and continuing clinical research and empiric treatment trials are appropriate."
Cannabis Bud
The takeaway here is something that might seem obvious to regular marijuana users: pot is good for pain. But it's not just good, it's safe. Even over-the-counter medication such as Tylenol carries risk of overdose if you take too much, threatening to damage your liver. Cannabis, on the other hand, has no serious side effects, and numerous studies have demonstrated that it is similarly effective at treating various types of pain.
What's remarkable about this potential health benefit is what it could mean in the context of America's heroin epidemic. According to the National Institute on Drug Abuse, abuse of painkillers directly correlates with the rise of heroin addiction in the U.S. If a person becomes addicted to prescription pain medication, there is a strong chance that they could transition to cheaper, more potent drugs such as heroin.

RELATED: Here's What Marijuana Does to Your Stress

But in states where pain patients have access to medical marijuana, the rate of fatal drug overdose is reduced, suggesting that pot is something of an "anti-gateway drug." By legalizing marijuana and allowing people to manage their pain with cannabis, we could effectively stop the cycle and help patients who might benefit from a safe and non-addictive alternative to pills.



Wednesday, August 12, 2015

Medical Marijuana States See Painkiller Deaths Drop by 25%

http://archinte.jamanetwork.com/article.aspx?articleid=1898878

Medical Cannabis Laws and Opioid Analgesic Overdose Mortality in the United States, 1999-2010

Marcus A. Bachhuber, MD1,2,3; Brendan Saloner, PhD3,4; Chinazo O. Cunningham, MD, MS5; Colleen L. Barry, PhD, MPP3,6
JAMA Intern Med. 2014;174(10):1668-1673. doi:10.1001/jamainternmed.2014.4005.
Text Size: A A A
Importance  Opioid analgesic overdose mortality continues to rise in the United States, driven by increases in prescribing for chronic pain. Because chronic pain is a major indication for medical cannabis, laws that establish access to medical cannabis may change overdose mortality related to opioid analgesics in states that have enacted them.
Objective  To determine the association between the presence of state medical cannabis laws and opioid analgesic overdose mortality.
Design, Setting, and Participants  A time-series analysis was conducted of medical cannabis laws and state-level death certificate data in the United States from 1999 to 2010; all 50 states were included.
Exposures  Presence of a law establishing a medical cannabis program in the state.
Main Outcomes and Measures  Age-adjusted opioid analgesic overdose death rate per 100 000 population in each state. Regression models were developed including state and year fixed effects, the presence of 3 different policies regarding opioid analgesics, and the state-specific unemployment rate.
Results  Three states (California, Oregon, and Washington) had medical cannabis laws effective prior to 1999. Ten states (Alaska, Colorado, Hawaii, Maine, Michigan, Montana, Nevada, New Mexico, Rhode Island, and Vermont) enacted medical cannabis laws between 1999 and 2010. States with medical cannabis laws had a 24.8% lower mean annual opioid overdose mortality rate (95% CI, −37.5% to −9.5%; P = .003) compared with states without medical cannabis laws. Examination of the association between medical cannabis laws and opioid analgesic overdose mortality in each year after implementation of the law showed that such laws were associated with a lower rate of overdose mortality that generally strengthened over time: year 1 (−19.9%; 95% CI, −30.6% to −7.7%; P = .002), year 2 (−25.2%; 95% CI, −40.6% to −5.9%; P = .01), year 3 (−23.6%; 95% CI, −41.1% to −1.0%; P = .04), year 4 (−20.2%; 95% CI, −33.6% to −4.0%; P = .02), year 5 (−33.7%; 95% CI, −50.9% to −10.4%; P = .008), and year 6 (−33.3%; 95% CI, −44.7% to −19.6%; P < .001). In secondary analyses, the findings remained similar.
Conclusions and Relevance  Medical cannabis laws are associated with significantly lower state-level opioid overdose mortality rates. Further investigation is required to determine how medical cannabis laws may interact with policies aimed at preventing opioid analgesic overdose.